Supply Chain Intelligence

Monopar Therapeutics Inc. Supply Chain

MNPR supply chain intelligence for Monopar Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MNPR ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

21Suppliers
0Customers
1Debt Items
20Related Chains

Monopar Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
ALEXION-PHARMACEUTICALS-INC ALEXION-PHARMACEUTICALS-INC 92% Alexion granted Monopar an exclusive worldwide license for the development and commercialization of ALXN1840
ALEXION ALEXION 90% We have also given Alexion the right of first negotiation regarding any rights should we intend to sublicense ALXN1840.
NORTHSTAR-MEDICAL-RADIOISOTOPES-LLC NORTHSTAR-MEDICAL-RADIOISOTOPES-LLC 90% NorthStar will provide Monopar with the therapeutic radioisotope actinium-225
XOMA XOMA Royalty Corporation 80% Reciprocal relationship from XOMA graph: Reciprocal relationship from MNPR graph: We also rely on certain rights to MNPR-101 that we have secured through a non-exclusive license agreement with XOMA.
XOMA XOMA Royalty Corporation 80% We also rely on certain rights to MNPR-101 that we have secured through a non-exclusive license agreement with XOMA.
ATNM Actinium Pharmaceuticals, Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
ATNM Actinium Pharmaceuticals, Inc. 72% Reciprocal relationship from ATNM graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from ATNM g…
BHC Bausch Health Companies Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
BHC Bausch Health Companies Inc. 72% Reciprocal relationship from BHC graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compou…
ETON Eton Pharmaceuticals, Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
ETON Eton Pharmaceuticals, Inc. 72% Reciprocal relationship from ETON graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently …
JNJ Johnson & Johnson 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compou…
LLY Eli Lilly and Company 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
LNTH Lantheus Holdings, Inc. 72% Reciprocal relationship from LNTH graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently…
LNTH Lantheus Holdings, Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
RARE Ultragenyx Pharmaceutical Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
RARE Ultragenyx Pharmaceutical Inc. 72% Reciprocal relationship from RARE graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from RARE graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from RARE g…
TLX Telix Pharmaceuticals Limited 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
TLX Telix Pharmaceuticals Limited 72% Reciprocal relationship from TLX graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently …

Monopar Therapeutics Inc. Customers

No clients on recordNo downstream customers found in our database for Monopar Therapeutics Inc..

Monopar Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
MNPR-DEBT Debt stack $230,425 90% Market cache reports total debt of $230,425.

Monopar Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Monopar Therapeutics Inc..

Monopar Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
MNPR-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 82 tracked holders.

Monopar Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
TLX Telix Pharmaceuticals Limited 100.00 1 ['supplier']
LLY Eli Lilly and Company 100.00 1 ['supplier']
JNJ Johnson & Johnson 100.00 1 ['supplier']
XOMA XOMA Royalty Corporation 100.00 1 ['supplier']
ATNM Actinium Pharmaceuticals, Inc. 100.00 1 ['supplier']
BHC Bausch Health Companies Inc. 100.00 1 ['supplier']
ETON Eton Pharmaceuticals, Inc. 100.00 1 ['supplier']
RARE Ultragenyx Pharmaceutical Inc. 100.00 1 ['supplier']
LNTH Lantheus Holdings, Inc. 100.00 1 ['supplier']
CYTOF Altamira Therapeutics Ltd. 50.00 2
AVBP ArriVent BioPharma, Inc. 50.00 2
AORT Artivion, Inc. 50.00 2
BIOA BioAge Labs, Inc. 50.00 2
FHTX Foghorn Therapeutics Inc. 50.00 2
CVRX CVRx, Inc. 50.00 2
BSX Boston Scientific Corporation 50.00 2
AXSM Axsome Therapeutics, Inc. 50.00 2
SWKHL SWK Holdings Corp 50.00 2
DAWN Day One Biopharmaceuticals Inc 50.00 2
BTAI BioXcel Therapeutics, Inc. 50.00 2
View MNPR supply chain intel →

Explore the full interactive supply chain map for Monopar Therapeutics Inc..

Open MNPR supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map